- Home
- ADMA
ADMA
ADMA Biologics Inc
as 07-31-2025 4:00pm EST
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
Upcoming Earnings Alert:
Get ready for potential market movements as ADMA Biologics Inc ADMA prepares to release earnings report on 06 Aug 2025.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | RAMSEY |
| Market Cap: | 5.1B | IPO Year: | N/A |
| Target Price: | $27.67 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.21 - $25.67 | Next Earning Date: | 08-06-2025 |
| Revenue: | $459,381,000 | Revenue Growth: | 62.23% |
| Revenue Growth (this year): | 21.11% | Revenue Growth (next year): | 25.97% |
Stock Insider Trading Activity of ADMA Biologics Inc (ADMA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Grossman Adam S | ADMA | President and CEO | Jun 16 '25 | Sell | $20.81 | 21,000 | $437,010.00 | 2,043,850 | |
| ELMS STEVE | ADMA | Director | Jun 12 '25 | Sell | $20.92 | 425,621 | $8,829,333.47 | 2,031,730 | |
| Guiheen Lawrence P. | ADMA | Director | Jun 9 '25 | Sell | $20.96 | 20,000 | $419,200.00 | 94,830 | |
| Guiheen Lawrence P. | ADMA | Director | May 21 '25 | Sell | $20.22 | 9,000 | $182,635.80 | 94,830 | |
| Grossman Adam S | ADMA | President and CEO | May 15 '25 | Sell | $19.45 | 21,000 | $408,450.00 | 2,043,850 |
Latest ADMA Biologics Inc News
ADMA Breaking Stock News: Dive into ADMA Ticker-Specific Updates for Smart Investing
Zacks
a month ago
Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note
Simply Wall St.
a month ago
Exploring Three High Growth Tech Stocks In The US Market
Zacks
a month ago
Implied Volatility Surging for ADMA Biologics Stock Options
Zacks
a month ago
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
Argus Research
a month ago
ADMA: Lowering target price to $19.00
Insider Monkey
a month ago
ADMA Biologics (ADMA) Drops 14.7% W/W as 3 Execs Unload Portfolios
Zacks
a month ago
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market
Simply Wall St.
a month ago
ADMA Biologics, Inc.'s (NASDAQ:ADMA) institutional investors lost 17% over the past week but have profited from longer-term gains
Compare ADMA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADMA ADMA Biologics Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.